New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

Boston, MA -- (SBWire) -- 09/04/2013 --Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection.

Victrelis is an anti-HCV drug marketed by Merck. Victrelis inhibits the HCV NS3/4A protease by reversibly binding to enzyme's active site. The HCV protease is required for viral polyprotein processing, which makes the enzyme essential for HCV replication (Asselah and Marcellin, 2013). The HCV protease is, therefore, an attractive drug target. Victrelis was a first-in-class DAA when it was approved in the US and EU in 2011 for the treatment of HCV GT1 infection.

View Full Report Details and Table of Contents

Scope

- Overview of Hepatitis C infection, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Victrelis including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Victrelis for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis C
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Victrelis performance
- Obtain sales forecast for Victrelis from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Hepatitis C Virus - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hepatitis C Virus - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hepatitis C Virus - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hepatitis C Virus - United States Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hepatitis C Virus - Brazil Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hepatitis C Virus - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hepatitis C Virus - China Drug Forecast and Market Analysis to 2022
- Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022